Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema.
| Date | Est. | Actual | |
|---|---|---|---|
| May 8, 2023 | -$0.45 | -$15.88 | Miss |
| Mar 9, 2023 | -$0.45 | -$0.41 | Beat |
| Nov 10, 2022 | -$0.44 | -$6.44 | Miss |
| Aug 11, 2022 | -$0.40 | -$5.32 | Miss |
| May 10, 2022 | -$0.38 | -$6.72 | Miss |
| Mar 10, 2022 | -$0.37 | -$5.74 | Miss |